Biovest International, a majority owned subsidiary of Accentia Biopharmaceuticals, added that the independent safety panel has requested an interim analysis of all primary and secondary endpoints. The company
The placebo-controlled trial will include approximately 120 patients with moderate to severe cancer-related pain. A primary composite endpoint that evaluates pain reduction with an improvement in quality of
This is the second $5 million payment to be received by Pharmacopeia, a company engaged in the discovery and development of novel small molecule therapeutics. This payment is
Elestrin (estradiol gel 0.06%) was approved for this application by the FDA in December 2006. Bradley in-licensed Elestrin, which is patent protected until 2022, from BioSante Pharmaceuticals in
Astion Pharma recently completed a phase I development program for the drug, ASF-1096, for the treatment of the serious skin disease, cutaneous lupus erythematosus. The results from the
UK-based Chroma said that it will shortly start its second phase II trial, in non-small cell lung cancer (NSCLC). This follows the recent initiation of a phase II
Professor Josef Smolen, Division of Rheumatology at the Medical University of Vienna, Austria and colleagues did a comprehensive study of the three new drugs – rituximab, abatacept and
The UK accountants predict that by 2020 the global pharmaceutical market will more than double in value to $1.3 trillion, driven by soaring worldwide demand for medicines and
Nalbuphine ER, designed to be taken as a twice-daily tablet, uses Penwest’s drug delivery technology. The main objective of this phase IIa study is to evaluate the analgesic
The trial was designed to study the interaction between valopicitabine, Idenix’s lead drug candidate for the treatment of hepatitis C, pegylated interferon and ribavirin compared to pegylated interferon
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.